Physician profile
Michael Malstrom
NPI 1386862316
$4,319.59
in general payments reported to CMS, 2019-2025
28 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $14.58 · 2021: $177 · 2022: $597 · 2023: $1,024 · 2024: $1,256 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.73 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $798.70 | 2020-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $419.57 | 2022-2025 | Xipere, Vyzulta, Visudyne |
| Oyster Point Pharma, INC. | $414.63 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $395.88 | 2019-2025 | Clareon, Argos, Tryptyr |
| Ani Pharmaceuticals, INC. | $141.76 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Sun Pharmaceutical Industries INC. | $138.19 | 2019-2025 | Cequa |
| Harrow Eye, LLC | $103.88 | 2024-2025 | Vevye |
| Astellas Pharma US INC | $83.28 | 2023-2025 | Izervay |
| Amgen INC. | $82.53 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $79.86 | 2019-2022 | |
| Eyepoint US, INC. | $78.73 | 2022 | |
| Allergan, INC. | $76.11 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $65.64 | 2022-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Dompe US, INC. | $65.52 | 2025 | Oxervate |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $54.84 | 2024 | Cimerli |
| Apellis Pharmaceuticals, INC. | $49.62 | 2024-2025 | Syfovre |
| Shire North American Group INC | $48.71 | 2019 | |
| Genentech USA, INC. | $46.12 | 2023 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $35.12 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.60 | 2021 | |
| Thea Pharma INC. | $30.53 | 2022-2024 | Iyuzeh |
| Stimwave Technologies Incorporated | $23.27 | 2021 | |
| Alcon Research LLC | $14.38 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.26 | 2024 | Acthar |
| Horizon Therapeutics Plc | $12.81 | 2022 | |
| Ocular Therapeutix, INC. | $12.23 | 2019 | |
| Vyera Pharmaceuticals, LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Malstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.